Evaluating Cosmetics Manufacturers: The Checklist for Brands Before Making a Choice
Evaluating Cosmetics Manufacturers: The Checklist for Brands Before Making a Choice
12 min read
CEO & Founder at Labtree GmbH
The choice of manufacturer is one of the most consequential decisions for cosmetics brands. Anyone who conducts a systematic evaluation avoids late surprises. The eight central points.
Topics on this page
The topic is short and compact
Eight testing points: formulation base, laboratory, test batch, sampling, parallel implementation, scaling, documentation, delivery reliability.
For integrated development partners, all areas are covered; specialized profiles have strengths and gaps.
Systematic evaluation before selection avoids late surprises, incorrect costs, long time-to-market, supply issues, and regulatory gaps.
What to check: Does the manufacturer have its own library of realistically feasible formulations? How broad is it? Are the formulations already stability-tested and regulatorily prepared?
Why it matters: A formulation base saves development time. Brands do not start into the unknown, but adapt an existing base. At Labtree, the base includes more than 1,000 of our own formulations.
Point 1: formulation base
What to check: Does the manufacturer have its own library of realistically feasible formulations? How broad is it? Are the formulations already stability-tested and regulatorily prepared?
Why it matters: A formulation base saves development time. Brands do not start into the unknown, but adapt an existing base. At Labtree, the base includes more than 1,000 of our own formulations.
Point 2: In-house laboratory development
What to check: Does the manufacturer have its own laboratory? Are adjustments made in-house, or through external service providers?
Why it matters: External laboratories mean additional interfaces and waiting times. In-house competence allows for faster iteration and closer integration with production.
Point 3: Test batch capability
What to check: Can test batches be created under production-like conditions before investing in industrial scaling?
Why it matters: Test batches are the bridge between laboratory trials and routine production. They show whether the formulation actually runs consistently under production conditions.
Point 4: Sampling speed
What to check: How quickly are the first physical samples available? How quickly do adjustments follow after feedback?
Why it matters: Early physical samples shift decisions from theory to reality. Standard samples within 24 hours is a realistic benchmark.
Point 5: Parallel implementation of packaging and approval
What to check: Are packaging selection, design requirements, and regulatory topics considered in parallel with formulation development?
Why it matters: Sequential handovers are the most common cause of launch delays. Early parallel processing, preparatory steps for safety assessment and PIF in parallel with the formulation, final approval after completion, accelerates time-to-market by up to 50 percent.
In-depth sources: The legal basis for all cosmetic products distributed in the EU is the EU Cosmetics Regulation (EC) No. 1223/2009. The health assessment of ingredients in Germany lies with the Federal Institute for Risk Assessment (BfR). Industry information and market data are published by the German Cosmetic, Toiletry, Perfumery and Detergent Association (IKW).
Point 6: Scalability
What to check: Can the manufacturer deliver from prototype to mass production? How is production feasibility taken into account during the prototyping phase?
Why it matters: The transition from test batch to industrial production is one of the most dangerous moments in the project. An integrated setup with early production involvement reduces the risk.
Related articles: Cosmetics manufacturers in Germany · Switching cosmetic manufacturers · Switching manufacturers too late
What to check: Are PIF, CPNP notification, and safety assessment part of the standard process? How is the documentation maintained and provided during audits?
Why it matters: Incomplete documentation is a risk for market authorization and listings. It also significantly complicates subsequent manufacturer changes.
What to check: References regarding delivery reliability over several years. Communication structure: how quickly and how transparently are status inquiries answered?
Why it matters: Even technically good production is of little use if delivery commitments are unreliable or communication during the project is non-transparent.
The eight test points provide a complete picture of the manufacturer's positioning. For integrated development partners like Labtree, all points are structurally covered. For specialized profiles, the strengths vary; the brand must decide which points are critical for its requirements.
More useful links
FAQ
Does Labtree have its own laboratory?
Yes. Labtree has its own development expertise, including a laboratory. This means that formulations can not only be selected, but specifically developed, tested, and adjusted. Additionally, smaller test batches can be produced in-house in order to validate products early on in real conditions and safely transfer them to production.
Which checkpoint is the most important?
Depends on the requirement. For time-to-market-critical projects, formulation basis and parallel implementation are most important. For innovation projects, your own laboratory development and test-batch capability are of secondary importance. For listings, regulatory documentation and reliability of supply are key.
How do I recognize whether a manufacturer actually meets these points?
Through specific questions with verifiable answers: number of formulations, availability of sample shipping times, references to comparable projects, audit readiness of documentation. General statements without proof are a warning sign.
How much does a systematic manufacturer check cost?
Done in-house: primarily time for structured inquiries and reference checks. Externally: consulting services depending on the depth. In any case, more cost-effective than later surprises due to a wrong selection.
What are the red flags?
Incomplete regulatory documentation, long wait times for samples, lack of in-house laboratory expertise, missing references for scaling projects, and non-transparent communication during the initiation phase.
Should I inquire with multiple manufacturers at the same time?
Yes. Three structured quotes allow for a meaningful comparison. Important: formulate the inquiries consistently, otherwise the answers will not be comparable.
Now discover more articles
